BioConnection to manufacture clinical trial material for Nykode Therapeutics’ vaccine

BioConnection, an independent CDMO (Contract Development Manufacturing Organization) based in Oss, The Netherlands, specialized in GMP-certified manufacturing of sterile drug products in vials and syringes, today announced that Nykode Therapeutics AS, (formerly Vaccibody) (Euronext Growth Oslo: VACC), selected BioConnection for the aseptic drug product manufacturing of its lead vaccine candidate. Nykode Therapeutics AS is a clinical stage biotechnology company, developing vaccines and novel immunotherapies for the treatment of cancer and infectious diseases with a high unmet medical need.

Mette Husbyn, CTO of Nykode Therapeutics, said:
“We chose to partner with BioConnection for the manufacturing of Nykode Therapeutics’ precious clinical trial material because of their tailored solutions for production, matching the requirements for small scale batches. Moreover, BioConnection has an excellent broad manufacturing and regulatory track record, including EMA and FDA certification.”

BioConnection’s CEO Alexander Willemse adds:
“Phase I trials usually require small batches of drug products that have to be delivered in a precise manner. Capitalizing on our years of experience, we offer automated filling in large volumes up to 40 million vials per year, and importantly also manual fill and finish. I’m very happy that our manufacturing capabilities, perfectly match Nykode Therapeutics’ exact early phase clinical trial needs.”